Applications for digital PCR in oncology are myriad, from biomarker discovery to early detection, liquid biopsy research as well as monitoring recurrence and response to treatment. For all applications in translational cancer research, the Absolute Q digital PCR platform brings 4-color multiplexing capabilities, improved sensitivity, and a one-step, walkaway workflow to your application.
Identifying oncogenic mutations via liquid biopsy can be used for early detection, measuring therapeutic response, quantifying residual disease, and monitoring emerging resistance to targeted therapies. Here, we demonstrate compatibility with Applied Biosystems™ TaqMan™ Liquid Biopsy assays, performing robust detection of 5 different hotspot mutations down to 0.1% allelic frequency. See the TaqMan protocol here.
In this publication in Scientific Reports, Combinati shows the capability of the Absolute Q to to detect and quantify non-small cell lung carcinoma (NSCLC) rare genetic mutants (EGFR T790M) with precision cell-free DNA (cfDNA) standards.
Tyrosine kinase inhibitors are a cornerstone of precision medicine and are a standard of care for those harboring oncogenic mutations. Unfortunately, drug-resistant mutations are a common result of this treatment. Sensitive and precise detection of these variants are critical to make well-informed treatment decisions. See how the Absolute Q was used alongside an existing two-enzyme PCR chemistry to enable highly precise interrogation of challenging genomic regions, identifying EGFR pT790M mutations down to 5 copies per reaction – all without the need for a standard curve.
Luminex uses the Combinati Absolute Q platform to identify underlying mechanisms of drug resistance in metastatic breast cancer with Luminex multiplex PCR chemistry.
Highlights of this webinar include:
Find out more about harnessing the
power of Digital PCR for your research.
Combinati believes simplicity shouldn’t require sacrificing robustness, quality, or rigor – in fact, it should enable it. Our easy-to-use digital PCR platform offers absolute quantification to track disease-relevant biomarkers over time with high accuracy and precision. Our core microfluidic technology, single instrument, and single consumable together enable consistent partitioning of samples with minimal sample waste.
Combined with the ability to robustly reject false positives and easily adapt traditional qPCR assays, Combinati aims to democratize digital PCR for researchers all over the world.
For research use only. Not for use in diagnostic procedures.
Copyright ©2021 Combinati
SIGN UP FOR PRODUCT NEWS
